Chronic Mucocutaneos Candidiasis is the most severe mucosal manifestation of candida infections. Almost all times, this is an intrinsic immune defect since we were born.
It is extremely difficult to achieve cure or remission of it.
See this case :
Case report: successful treatment with cimetidine and zinc sulphate in chronic mucocutaneous candidiasis.
Polizzi B, Origgi L, Zuccaro G, Matti P, Scorza R.
Institute of Internal Medicine, Infectious Disease and Immunopathology, Univerity of Milan, Italy.
The authors evaluated the clinical efficacy of a treatment with cimetidine and zinc sulphate in a patient with chronic mucocutaneous candidiasis. Cimetidine was given at a dose of 400 mg three times daily; zinc sulphate at a dose of 200 mg daily, then adjusted to maintain blood zinc levels at the upper normal range. This treatment lasted 16 months. An impressive and significant reduction of the infectious events and an increased CD4 (helper/inducer) cell counts were observed. The authors conclude that this combined immunopotentiating treatment is safe and inexpensive to treat immunodeficiency disorders.
I say if Cimetidine was successful in this recalcitrant case, it must be in many cases of Candida Related Complex when the immune suppression is mostly acquired during life.
I have to be honest, since I am in this battle I haven't found anything more interesting than Cimetidine. The reason is you have it over the counter very cheap and the immune modulator effects are out of question, specially the increase of cell-mediated immunity and histamine reduction. High histamine depresses the immune response...
This is something that really should be considered and thought.
Here is clear too:
Cimetidine as an immunomodulator: chronic mucocutaneous candidiasis as a model.
Jorizzo JL, Sams WM Jr, Jegasothy BV, Olansky AJ.
Four adult patients with chronic mucocutaneous candidiasis were studied to establish a possible role for cimetidine as an immunomodulator. These patients had negative baseline in-vivo and in-vitro cell-mediated immune response to candida antigen as measured by intradermal skin tests, lymphocyte transformation, and leukocyte migration inhibitory factor production to cimetidine, 300 mg by mouth, four times daily. Subsequently four of four patients developed strong (greater than 15 mm) intradermal skin test reactions, and two of four patients produced leukocyte migration inhibitory factor to candida antigen. Skin tests and leukocyte migration inhibitory factor production reverted to baseline negative values when repeated 4 weeks after discontinuation of therapy. After 4 additional weeks on cimetidine, four of four patients showed strong positive skin tests and leukocyte migration inhibitory factor production to candida antigen. Lymphocyte transformation was not affected by therapy.